As the #1 respiratory hospital in the country National Jewish Health (NJH) offers expertise on all lung conditions, including the leading cause of cancer-related deaths—lung cancer. The hospital's Oncology Division is dedicated to the diagnosis, treatment and long-term follow-up and surveillance of individuals with known or suspected lung or thoracic cancers.
NJH has been a consortium member since 1985. In 2009, NJH committed $10 million to develop a translational and clinical research program in lung cancer. This program enhances the significant investments and research expertise already in place at the CU Cancer Center, such as the Lung Cancer SPORE.
A satellite facility of the Flow Cytometry Shared Resource exists at National Jewish Health.
National Jewish Health
Division of Oncology
Consortium Advisory Committee Representative
Jeffrey Kern, MD